Resultados de búsqueda - Sheng-Bin Peng

  • Mostrando 1 - 18 Resultados de 18
Limitar resultados
  1. 1
    LncRNA TTN-AS1 contributes to gastric cancer progression by acting as a competing endogenous RNA of miR-376b-3p

    LncRNA TTN-AS1 contributes to gastric cancer progression by acting as a competing endogenous RNA of miR-376b-3p por Mingming Dong, Sheng‐Bin Peng, Yan-hua Yuan, Hongqin Luo

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

    Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma por Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn T. Estrem, Shuyu Li, Xueqian Gong, Sean G. Buchanan, James R. Henry, James J. Starling, Sheng-Bin Peng

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

    The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation por Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean G. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, Sheng-Bin Peng

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

    A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models por Genshi Zhao, Weiying Li, Daohong Chen, James R. Henry, Hongyu Li, Zhaogen Chen, Mohammad Zia‐Ebrahimi, Laura J. Bloem, Yan Zhai, Karen Huss, Sheng‐Bin Peng, Denis McCann

    Publicado 2011
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies

    Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies por Sheng-Bin Peng, Xiaoyi Zhang, Donald C. Paul, Lisa Kays, Ming Ye, Peter Vaillancourt, Michele Dowless, Louis F. Stancato, Julie Stewart, Mark Uhlik, Haiyan Long, Shaoyou Chu, Victor H. Obungu

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer

    LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer por Eliza Vakana, Susan E. Pratt, Wayne Blosser, Michele Dowless, Nicholas Simpson, Xiu‐Juan Yuan, Susan Jaken, Jason R. Manro, Jennifer R. Stephens, Youyan Zhang, Lysiane Huber, Sheng-Bin Peng, Louis F. Stancato

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

    Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors por Mark H. O’Hara, Wells A. Messersmith, Hedy L. Kindler, Wei Zhang, Celine Pitou, Anna M. Szpurka, Dan Wang, Sheng-Bin Peng, Burkhard Vangerow, Anis A. Khan, Mythili Koneru, Andrea Wang‐Gillam

    Publicado 2020
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models

    Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models por Sheng-Bin Peng, Xiaoyi Zhang, Donald C. Paul, Lisa Kays, Wendy H. Gough, Julie Stewart, Mark Uhlik, Qi Chen, Yu‐Hua Hui, Maciej J. Zamek‐Gliszczynski, John A. Wijsman, Kelly M. Credille, Liang Yan

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

    Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy por Byung-Sik Cho, Zhihong Zeng, Hong Mu, Zhiqiang Wang, Sergej Konoplev, Teresa McQueen, Marina Protopopova, Jorge E. Cortés, Joseph R. Marszalek, Sheng‐Bin Peng, Wencai Ma, R. Eric Davis, Donald Thornton, Michael Andreeff, Marina Konopleva

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

    Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120 por Shih-Hsun Chen, Youyan Zhang, Robert D. Van Horn, Tinggui Yin, Sean G. Buchanan, Vipin Yadav, Igor Mochalkin, Swee Seong Wong, Yong Yue, Lysiane Huber, Ilaria Conti, James R. Henry, James J. Starling, Gregory D. Plowman, Sheng-Bin Peng

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets

    Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets por Ying Chen, Jeremy McGee, Xian‐Ming Chen, Thompson N. Doman, Xueqian Gong, Youyan Zhang, Nicole Hamm, Xiwen Ma, Richard E. Higgs, Shripad V. Bhagwat, Sean G. Buchanan, Sheng-Bin Peng, Kirk A. Staschke, Vipin Yadav, Yong Yue, Hosein Kouros‐Mehr

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Novel Lipoglycopeptides as Inhibitors of Bacterial Signal Peptidase I

    Novel Lipoglycopeptides as Inhibitors of Bacterial Signal Peptidase I por Palaniappan Kulanthaivel, A J Kreuzman, Mark A. Strege, Matthew D. Belvo, Tim A. Smitka, Matthew Clemens, James R. Swartling, Kristina L. Minton, Feng Zheng, Eddie L. Angleton, DEBORAH L. MULLEN, Louis N. Jungheim, Valentine J. Klimkowski, Thalia I. Nicas, R. C. Thompson, Sheng-Bin Peng

    Publicado 2004
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> Mutations

    Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> Mutations por Yung-Mae Yao, Gregory P. Donoho, Philip W. Iversen, Youyan Zhang, Robert D. Van Horn, Amélie Forest, Ruslan D. Novosiadly, Yue Webster, Philip J. Ebert, Steven M. Bray, Jason C. Ting, Amit Aggarwal, James R. Henry, Ramón V. Tiu, Gregory D. Plowman, Sheng‐Bin Peng

    Publicado 2017
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

    A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer por Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodón, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramón V. Tiu, David S. Hong

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  15. 15
    ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

    ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine por Shripad V. Bhagwat, William T. McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Weihua Shen, Lisa Kindler, Robert S. Flack, Wenjuan Wu, Bryan D. Anderson, Yan Zhai, Xiu‐Juan Yuan, Meghann Pogue, Robert D. Van Horn, Xi Rao, Denis McCann, Andrew J. Dropsey, Jason R. Manro, Jennie Walgren, Eunice Yuen, Michael Rodriguez, Gregory D. Plowman, Ramón V. Tiu, Sajan Joseph, Sheng-Bin Peng

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

    Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers por Irem Ozkan‐Dagliyan, J. Nathaniel Diehl, Samuel D. George, Antje Schaefer, Bjoern Papke, Kathleen Klotz‐Noack, Andrew M. Waters, Craig M. Goodwin, Prson Gautam, Mariaelena Pierobon, Sen Peng, Thomas S.K. Gilbert, Kevin Lin, Onur Dağliyan, Krister Wennerberg, Emanuel F. Petricoin, Nhan L. Tran, Shripad V. Bhagwat, Ramón V. Tiu, Sheng-Bin Peng, Laura E. Herring, Lee M. Graves, Christine Sers, Kris C. Wood, Adrienne D. Cox, Channing J. Der

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

    Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers por Sheng-Bin Peng, James R. Henry, Michael D. Kaufman, Wei-Ping Lu, Bryan D. Smith, Subha Vogeti, Thomas J. Rutkoski, Scott Wise, Lawrence Chun, Youyan Zhang, Robert D. Van Horn, Tinggui Yin, Xiaoyi Zhang, Vipin Yadav, Shih-Hsun Chen, Xueqian Gong, Xiwen Ma, Yue Webster, Sean G. Buchanan, Igor Mochalkin, Lysiane Huber, Lisa Kays, Gregory P. Donoho, Jennie Walgren, Denis McCann, Phenil J. Patel, Ilaria Conti, Gregory D. Plowman, James J. Starling, Daniel L. Flynn

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

    Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Pa... por James R. Henry, Michael D. Kaufman, Sheng-Bin Peng, Yu Mi Ahn, Timothy M. Caldwell, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Wei-Ping Lu, Molly M. Hood, Thomas J. Rutkoski, Bryan D. Smith, Subha Vogeti, David F. Miller, Scott Wise, Lawrence Chun, Xiaoyi Zhang, Youyan Zhang, Lisa Kays, Philip A. Hipskind, A.D. Wrobleski, Karen L. Lobb, Julia M. Clay, Jeffrey Cohen, Jennie Walgren, Denis McCann, Phenil J. Patel, David K. Clawson, Sherry Guo, Danalyn Manglicmot, C. Groshong, Cheyenne Logan, James J. Starling, Daniel L. Flynn

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: